What Happened?
Washington, DC-based Regenxbio Appointed Vit Vasista as Chief Financial Officer
About the Company
Regenxbio was formed from a successful collaboration that began in February 2009 between FoxKiser LLP, the University of Pennsylvania and gene therapy pioneer James M. Wilson, M.D., Ph.D. The foundation of our NAV Technology Platform was discovered in an effort to identify next generation AAV vectors that could overcome the limitations of earlier generation AAV vectors (AAV1 through AAV6).
About the Person
Vit Vasista is the Chief Financial Officer and Senior Vice President of Corporate Development at REGENXBIO. Prior to joining REGENXBIO, Mr. Vasista served as Principal at PRTM Management Consultants, where he developed operational strategies for both private and public organizations, including the development of market entry strategies, innovative business models, and operational improvements.
Info Source
Company Announcement
Short Profile